SimonMed launched an elective whole-body MRI screening line — a growth move radiology experts say raises questions about value and incidental-finding harms for average-risk patients.
In January 2026 SimonMed launched ‘SimonMed Longevity,’ an elective whole-body MRI screening program (reported expanding from about 30 to 70 sites, with packages priced roughly $899–$2,199) (Radiology Business). Whole-body screening of average-risk, asymptomatic people is clinically contested: professional bodies including the American College of Radiology have questioned its value and warned that incidental findings can lead to unnecessary follow-up tests and patient anxiety (HIT Consultant). This entry notes the launch as context for how the private-equity-owned company is expanding; the clinical debate is attributed to the cited coverage.